Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Visceral obesity with and without metabolic syndrome: incidence and clinical impact in esophageal adenocarcinoma treated with curative intent.

Authors:
Jessie A Elliott Noel E Donlon Peter Beddy Claire L Donohoe Suzanne L Doyle Sinead King Narayanasamy Ravi John V Reynolds

Dis Esophagus 2022 Jan 17. Epub 2022 Jan 17.

Visceral obesity (VO) and metabolic syndrome (MetS) are risk factors for esophageal adenocarcinoma (EAC); however, their impact on operative and oncological outcomes is unclear. The aim of this study was to determine the incidence of VO and MetS among patients with EAC, and to assess their independent impact on operative and oncological outcomes. A total of 454 consecutive patients undergoing treatment with curative intent were studied. Total, subcutaneous, visceral fat area (VFA), and lean body mass (LBM) were measured by computed tomography pretreatment, with VO defined as VFA >163.8cm2 for men and 80.1cm2 for women. MetS was defined per the ATPIII definition. Multivariable logistic and Cox proportional hazards regression were utilized to determine independent predictors of oncologic and operative outcomes. A total of 227 patients (50.0%) had VO. A total of 134 (30%) overall had MetS, 44% in the VO cohort. VO was associated with Barrett's esophagus (P = 0.002) and lower cT (P = 0.006) and cN stage (P = 0.011), and improved disease-specific (P = 0.021) and overall survival (P = 0.012). No survival benefit existed for patients with VO who also had MetS. For operative complications, neither VO nor MetS increased the severity of complications, or mortality. However, VO was significantly (P = 0.035) associated with anastomotic leak and pneumonia (P = 0.037). MetS alone did not increase complication risk. VO increases specific major operative complications with no increase in mortality. VO improved survival, mainly relating to earlier stage disease; however, co-existent MetS abrogated this benefit. These seemingly paradoxical outcomes highlight manageable and potentially targetable perioperative challenges in the context of an overall favorable oncologic vista.

Download full-text PDF

 Source
http://dx.doi.org/10.1093/dote/doab094DOI Listing
January 2022

Publication Analysis

Top Keywords

esophageal adenocarcinoma
8
visceral obesity
8
oncological outcomes
8
curative intent
8
operative oncological
8
mets
8
impact operative
8
metabolic syndrome
8
outcomes total
8
obesity metabolic
8
operative complications
8
operative
5
44% cohort
4
cohort associated
4
associated barrett's
4
barrett's esophagus
4
esophagus p = 0002
4
oncologic vista
4
p = 0002 lower
4
30% mets
4

Keyword Occurance

Similar Publications

Comparative Study of Pyloromyotomy and H-M Pyloroplasty in Proximal Gastrectomy for Adenocarcinoma of Esophageal-Gastric Junction.

Authors:
Mengyao Shi Zunqi Hu Kaiming Wu Dejun Yang Hongbing Fu Juanjuan Zhang Dong Li Weimin Wang Weijun Wang Zhenxin Zhu

J Gastrointest Surg 2022 May 18. Epub 2022 May 18.

Department of Gastro-Intestine Surgery, Shanghai Changzheng Hospital, Naval Medical University, 415 FengYang Road, Shanghai, 200003, People's Republic of China.

Introduction: The incidence of adenocarcinoma of esophageal-gastric junction (AEJ) has been increasing in recent years. Esophagogastrostomy after proximal gastrectomy (PG-EG) is the most commonly used surgical method for this disease which causes a constant spasm of the pyloric sphincter by cutting the vagus nerve around the esophagus, so H-M pyloroplasty (Heineke-Mikulicz pyloroplasty) is often operated after PG-EG to prevent delayed gastric emptying. However, H-M pyloroplasty destroys anti-reflux structure of pylorus and leads to serious bile reflux. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Role of sirtuins in esophageal cancer: Current status and future prospects.

Authors:
Ryota Otsuka Koichi Hayano Hisahiro Matsubara

World J Gastrointest Oncol 2022 Apr;14(4):794-807

Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Esophageal cancer (EC) is a malignant cancer that still has a poor prognosis, although its prognosis has been improving with the development of multidisciplinary treatment modalities such as surgery, chemotherapy and radiotherapy. Therefore, identifying specific molecular markers that can be served as biomarkers for the prognosis and treatment response of EC is highly desirable to aid in the personalization and improvement of the precision of medical treatment. Sirtuins are a family of nicotinamide adenine dinucleotide (NAD+)-dependent proteins consisting of seven members (SIRT1-7). Read More

View Article and Full-Text PDF
April 2022
Similar Publications

ZFPM2-AS1: An Oncogenic Long Non-coding RNA in Multiple Cancer Types.

Authors:
Fangshun Tan

Mini Rev Med Chem 2022 May 16. Epub 2022 May 16.

Medical College, China Three Gorges University, Yichang 443002, China.

Long non-coding RNA (lncRNA) is a novel kind of RNA transcript with lengths greater than 200 nucleotides. Functionally, lncRNAs lack the potential to encode peptides or proteins. Previous studies unveiled that lncRNA participated in numerous physiological and pathological processes, including cancer, aging, and immune responses. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer.

Authors:
David T Pointer Jordan A McDonald Samer A Naffouje Rutika Mehta Jason B Fleming Jacques P Fontaine Gregory Y Lauwers Jessica M Frakes Sarah E Hoffe Jose M Pimiento

J Surg Oncol 2022 May 16. Epub 2022 May 16.

Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

Background And Objectives: The gold standard for locoregional esophageal cancer (LEC) treatment includes preoperative chemoradiation and surgical resection, with possible perioperative or adjuvant systemic therapy. With few data associating histologic grade and prognosis in LEC patients receiving neoadjuvant chemoradiation followed by resection, we seek to evaluate this association.

Methods: Our institutional esophagectomy database between 1999 and 2019 was queried, selecting esophageal adenocarcinoma patients who completed neoadjuvant therapy (NAT), followed by esophagectomy. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

CSF2RB Is a Unique Biomarker and Correlated With Immune Infiltrates in Lung Adenocarcinoma.

Authors:
Ningning Zhu Yueyang Yang Haitong Wang Peng Tang Hongdian Zhang Haiyan Sun Lei Gong Zhentao Yu

Front Oncol 2022 28;12:822849. Epub 2022 Apr 28.

Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital; National, Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Background: The tumor microenvironment plays an important role in the occurrence and development of tumors. However, there are gaps in understanding the molecular and cellular interactions between tumor cells and the immune tumor microenvironment (TME). The aim of this study was to identify a novel gene that played an important role in the tumor microenvironment of lung adenocarcinoma (LUAD). Read More

View Article and Full-Text PDF
April 2022
Similar Publications
}